Ovid Therapeutics Files 8-K
Ticker: OVID · Form: 8-K · Filed: 2024-06-17T00:00:00.000Z
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Ovid Therapeutics filed a standard 8-K, no major news.
AI Summary
Ovid Therapeutics Inc. filed an 8-K on June 17, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the reporting of these items.
Why It Matters
This filing indicates Ovid Therapeutics is making disclosures and submitting financial statements, which is standard for public companies but doesn't reveal new material information on its own.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any specific new risks or material events.
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Registrant
- June 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 441 Ninth Avenue 14th Floor (address) — Principal Executive Offices
- New York, New York 10001 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Ovid Therapeutics Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 17, 2024.
In which U.S. state is Ovid Therapeutics Inc. incorporated?
Ovid Therapeutics Inc. is incorporated in Delaware.
What is the address of Ovid Therapeutics Inc.'s principal executive offices?
The address of Ovid Therapeutics Inc.'s principal executive offices is 441 Ninth Avenue, 14th Floor, New York, New York 10001.
Does this 8-K filing disclose any specific new material events or financial results?
This 8-K filing does not disclose any specific new material events or financial results; it primarily serves to report on Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-17 07:10:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Mar
Filing Documents
- ovid-20240617.htm (8-K) — 39KB
- ovid-ex99_1.htm (EX-99.1) — 45KB
- img34400995_0.jpg (GRAPHIC) — 29KB
- 0000950170-24-073998.txt ( ) — 243KB
- ovid-20240617.xsd (EX-101.SCH) — 24KB
- ovid-20240617_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 17, 2024, Ovid Therapeutics Inc. (the "Company") issued a press release reporting on Takeda Pharmaceutical Company Limited's Announcement of Phase 3 topline study results for soticlestat. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K The information,provided in this Item 7.01 including the Exhibit 99.1 hereto, is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act, only if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Exhibit No. Description 99.1 Press Release, dated June 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OVID THERAPEUTICS INC. Date: June 17, 2024 By: /s/ Thomas M. Perone General Counsel & Corporate Secretary